INC Research Latest Organization to Partner with SAS in Life Science Industry
Multiple partnerships formed over past year using SAS Drug Development, SAS Enterprise Intelligence Platform
PHILADELPHIA, June 19, 2006-INC Research® has selected SAS® Drug Development and the SAS® Enterprise Intelligence Platform for its clinical data analysis and integration, becoming the latest of numerous scientific and IT organizations that have combined SAS technology with their own products and services to solve life science industry problems.
The sale to INC Research-a leading contract research organization (CRO)-brings to more than 25 the number of life sciences organizations using SAS Drug Development, which provides a centralized, integrated system for managing, analyzing, reporting and reviewing clinical research information.
"Even as compliance pressures continue to mount and profits continue to tighten, life science companies remain eager for a system capable of the longitudinal analysis of clinical trial data," said Chris Connor, Senior Research Analyst at IDC Health Industry Insights. "A data integration and analysis solution that can, in a cost-effective manner, simultaneously integrate clinical, operational and financial data is critical to the ability to conduct adaptive trials and enables life science companies to compete in a market growing ever more uncertain. The capabilities of SAS Drug Development, when combined with the flexibility of deploying at the customer premises or as a hosted solution, offer a compelling solution for life science companies."
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
